ProfileGDS5678 / 1424317_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 61% 61% 56% 61% 61% 60% 66% 61% 62% 62% 61% 62% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.572559
GSM967853U87-EV human glioblastoma xenograft - Control 23.6656361
GSM967854U87-EV human glioblastoma xenograft - Control 33.6405461
GSM967855U87-EV human glioblastoma xenograft - Control 43.3561356
GSM967856U87-EV human glioblastoma xenograft - Control 53.6190561
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7455461
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6672360
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0132266
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6467761
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6617962
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6812262
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6430161
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6922562
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6556861